Alentis and PinotBio partner to develop claudin-1 oncology ADCs

Partnershipclaudin-1-targeting antibody-drug conjugatesPositive

AI Analysis

Summary

Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates for oncology indications.

Importance:5/10

Sentiment:

0.30

partnershiplicensing agreementADCclaudin-1oncologyresearch collaboration

Related Companies

$DFPH

Read the original article

Published by Pharmaceutical Technology on October 15, 2026 7:57 AM

Read Original